An observational study in Familial Mediterranean Fever, sponsored by Novartis Pharmaceuticals. Completed at 1 site in United States. Open to participants aged Up to 28 Years. Per ClinicalTrials.gov, last updated 2025-04-11.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A retrospective, non-interventional, single-center study conducted in Spain, based on the collection of data from the medical histories of patients with Familial Mediterranean fever (FMF) diagnosed during childhood from January 2005 to December 2021.
Data from the patients' medical records was collected retrospectively, from the time of diagnosis to the current moment of the patient's enrollment in the study. Patients had a minimum follow-up of 3 months after diagnosis.
61 studies on the registry are indexed under Familial Mediterranean Fever; 27 are open to participants now.
This study's enrollment of 44 is below the median of 89 across 30 observational studies indexed under Familial Mediterranean Fever.
Browse Familial Mediterranean Fever studies →Novartis Pharmaceuticals is the lead sponsor of 2,718 studies on the registry; 221 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 438 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
This was a retrospective, non-interventional cohort study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Spanish patients diagnosed with FMF during childhood from January 2005 to December 2021.
Number of Patients per Clinical Characteristic Category
Clinical characteristic categories included: * Diagnostic criteria of FMF (symptom associated with FMF, without a proven infectious cause, with a recurrent pattern and/or accompanied by a genetic test suggestive of Mediterranean FeVer gene \[MEFV\]) * Family history of FMF * MEFV genotypes * Phenotypes of interleukin-1 (IL-1) mediated autoinflammatory disease * Diagnosis prior to FMF
Time frame: Baseline
Clinical Characteristic: Time From FMF Diagnosis to Study Inclusion
Time frame: Baseline
Clinical Characteristic: Time From the Start of Symptomatology to Study Inclusion
Time frame: Baseline
Clinical Characteristic: Time From the Start of Symptomatology to FMF Diagnosis
Time frame: Baseline
Clinical Characteristic: Age at the Start of Symptomatology
Time frame: Baseline
Number of Patients by Symptomatology
Symptoms included: * Abdominal pain * Arthralgia * Myalgia * Articulatory inflammation * Chest pain * Rash * Fatigue * Symptoms compatible with Periodic Fever, Aphthous stomatitis, Pharyngitis and Adenitis (PFAPA) * Other
Time frame: Baseline, Month 3, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132
Number of Patients by Characteristics of Relapses (Flares)
Relapse characteristics included: * Fever: high (\> 38C), low (≤ 38C), no fever * Relapse frequency (\<1 or ≥1 relapse per month for 3 months) * Presence of triggers * Presence of complications * Flare and non-flare related inflammatory markers: C-reactive protein (CRP), serum amyloid A protein (SAA), and erythrocyte sedimentation rate (ESR) * Disease remission
Time frame: Baseline, Month 3, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132
Flare and Non-flare Related Inflammatory Marker Levels
Inflammatory markers included CRP and SAA.
Time frame: Baseline, Month 3, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132
Flare and Non-flare Related Erythrocyte Sedimentation Rate (ESR)
Time frame: Baseline, Month 3, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132
Number of Flares per Month Since Last Visit
Time frame: Baseline, Month 3, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132
Flare Duration Since Last Visit
Time frame: Baseline, Month 3, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132
Number of Patients With Recurrency of Flares at Diagnosis
Time frame: Baseline
Number of Patients by Comorbidity
Comorbidities included vasculitis, panniculitis, inflammatory bowel disease, psoriasis, celiac disease, autoimmune disease, other inflammatory diseases, juvenile idiopathic arthritis, multiple sclerosis, attention deficit hyperactivity disorder (ADHD), and other.
Time frame: Baseline, Month 3, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132
Number of Patients by Treatment Received Before FMF Diagnosis
Treatments included: * Non-steroidal anti-inflammatory drugs (NSAIDs) * Corticoids * Colchicine * Anti-IL-1 * Other
Time frame: Baseline
Number of Patients by Treatment Received At Least Once During the Study
Treatments included: * Colchicine * Canakinumab * Anakinra * Corticoids * Methotrexate (MTX) * Anti-IL-6 * Anti-tumor necrosis factor (TNF)
Time frame: Up to 11 years
Number of Patients by Treatment and Treatment Combinations Used at the end of the Study
Treatments and treatment combinations included: * Colchicine * Canakinumab * Anakinra * Corticoids * MTX * Anti-IL-6 * Anti-TNF * Colchicine / Canakinumab * Colchicine / Corticoids * Anakinra * Canakinumab * Colchicine / Anti-TNF * Colchicine / MTX / Anti-IL- 6
Time frame: Up to 11 years
Number of Patients Using Colchicine With Another Treatment at the end of the Study
Time frame: Up to 11 years
Number of Patients by First Prescribed Colchicine Dose and Age Group
Time frame: Up to 11 years
Number of Patients by Colchicine Maximum Global Dose and Age Group
Time frame: Up to 11 years
Number of Patients With a Change in Colchicine Dose
Time frame: Up to 11 years
Number of Patients by Reason for Stopping Colchicine Treatment and Age Group
Time frame: Up to 11 years
Number of Patients by Anti-IL-1 Treatment Used at the end of the Study
Anti-IL-1 treatment included canakinumab and anakinra.
Time frame: Up to 11 years
Number of Patients by Anti-IL-1 Dose at the end of the Study
Time frame: Up to 11 years
Number of Patients With a Change in Anti-IL-1 Dose
Time frame: Up to 11 years
Number of Patients With a Change in Anti-IL-1 Treatment
Changes in treatment included: * Change of treatment to a treatment of the same family (anti-IL-1) * Change of treatment to a treatment of another family
Time frame: Up to 11 years
Number of Patients by Reason for Stopping Anti-IL-1 Treatment
Time frame: Up to 11 years
Number of Patients by Last Reported Response to Colchicine Treatment
Responses included: * Complete response: absence of clinical manifestations and normal CRP/SAA levels. * Partial response: \<1 flare/month or persistent high CRP/SAA levels with maximum tolerated dose of colchicine or partial response with unknown frequency. * Resistant: ≥1 flare/month or persistent high CRP/SAA levels with maximum tolerated dose of colchicine. * Intolerant: intolerance to treatment as reason for stopping colchicine treatment or changing to another treatment.
Time frame: Up to 11 years
Time to Achieve Response to Colchicine Treatment
Time to achieve first complete response, complete response, and complete response maintenance were measured.
Time frame: Up to 11 years
Number of Patients With Intolerance to Colchicine Treatment
Time frame: Up to 11 years
Autoinflammatory Disease Activity Index (AIDAI) Score
The AIDAI is an assessment tool used to evaluate the level of disease activity. The AIDAI for FMF includes 7 variables: fever, abdominal pain, chest pain, arthralgia or myalgia, swelling of the joints, skin rash, and pain relief taken. Disease activity scores are calculated from the daily scores collected in a patient diary completed during flares. Fever is scored as 0 (absent) or present (1), with all other clinical variables scored from 0 (absent) to 3 (severe). Pain relief taken is not included in the disease activity score calculation. A higher total score indicates a higher level of disease activity. AIDAI was used to assess the association between disease activity and colchicine resistance/intolerance, response to canakinumab treatment, pain, fatigue, and quality of life (absenteeism at school during flares, limitation of physical activity, psychological care, and overall health status).
Time frame: Up to 11 years
Autoinflammatory Disease Damage Index (ADDI) Score
The ADDI is an assessment tool used to evaluate the level of damage caused by autoinflammatory disease. It consists of 18 damage items grouped by organ system: reproductive, renal/amyloidosis, developmental, serosal, neurological, ears, ocular and musculoskeletal damage. Each damage item is defined and assigned a score of 1, 2, or 3, with each organ system having a maximum allowed score. A higher total score indicates a higher level of damage. ADDI was used to assess the association between disease damage and colchicine resistance/intolerance, response to canakinumab treatment, pain, fatigue, and quality of life (absenteeism at school during flares, limitation of physical activity, psychological care, and overall health status).
Time frame: Up to 11 years
Familial Mediterranean Fever 50 (FMF50) Score
The FMF50 is an assessment tool used to evaluate response to treatment for FMF. It consists of 6 items: 1. Percentage change in the frequency of attacks with the treatment. 2. Percentage change in the duration of attacks with the treatment. 3. Patients/parents' global assessment of disease severity. 4. Physicians' global assessment of disease severity. 5. Percentage change in arthritis attacks with the treatment. 6. Percentage change in CRP, ESR, or SAA level with the treatment. An improvement of at least 50% in 5 of the 6 items without worsening in any one item indicates that the patient is responding to treatment. FMF50 was used to assess response to canakinumab treatment and the association between response to treatment and colchicine resistance/intolerance, pain, fatigue, and quality of life (absenteeism at school during flares, limitation of physical activity, psychological care, and overall health status).
Time frame: Up to 11 years
Number of Patients by Last Response Reported to Anti-IL-1 Treatment During the Study
Responses included: * Complete response: absence of clinical manifestations and normal CRP/SAA levels. * Incomplete response: persistent febrile episodes or high CRP/SAA levels * Partial response: \<1 flare/month or persistent high CRP/SAA levels with maximum tolerated dose of colchicine or partial response with unknown frequency. * Resistant: ≥1 flare/month or persistent high CRP/SAA levels with maximum tolerated dose of colchicine. Anti-IL-1 treatments included canakinumab and anakinra.
Time frame: Up to 11 years
Time to Achieve Response to Anti-IL-1 Treatment
Time to achieve complete response and complete response maintenance were measured. Anti-IL-1 treatments included canakinumab and anakinra.
Time frame: Up to 11 years
Number of Patients With MEFV Mutation by Treatment Response
Response categories included: * Respondent: without flares and with normal inflammatory markers in the last 3 months. * Non-respondent: with flare and/or elevated inflammatory markers in the last 3 months. * Partial respondent: did not fulfill some of the criteria for complete response.
Time frame: Up to 11 years
Number of Patients Without MEFV Mutation by Treatment Response
Response categories included: * Respondent: without flares and with normal inflammatory markers in the last 3 months. * Non-respondent: with flare and/or elevated inflammatory markers in the last 3 months. * Partial respondent: did not fulfill some of the criteria for complete response.
Time frame: Up to 11 years
Number of Patients With Mutation in Other Loci by Treatment Response
Response categories included: * Respondent: without flares and with normal inflammatory markers in the last 3 months. * Non-respondent: with flare and/or elevated inflammatory markers in the last 3 months. * Partial respondent: did not fulfill some of the criteria for complete response.
Time frame: Up to 11 years
Number of Medical Visits of Patients With Scholar Absenteeism During Flares by Response to Anti-IL-1 Treatment
Anti-IL-1 treatments included canakinumab and anakinra. Responses were categorized as follows: * Respondent: without flares and with normal inflammatory markers in the last 3 months. * Non-respondent: with flare and/or elevated inflammatory markers in the last 3 months. * Partial respondent: did not fulfill some of the criteria for complete response.
Time frame: Up to 11 years
Number of Medical Visits of Patients With Physical Activity Limitations by Response to Anti-IL-1 Treatment
Anti-IL-1 treatments included canakinumab and anakinra. Responses were categorized as follows: * Respondent: without flares and with normal inflammatory markers in the last 3 months. * Non-respondent: with flare and/or elevated inflammatory markers in the last 3 months. * Partial respondent: did not fulfill some of the criteria for complete response.
Time frame: Up to 11 years
Number of Medical Visits of Patients Requiring Psychological Care by Response to Anti-IL-1 Treatment
Anti-IL-1 treatments included canakinumab and anakinra. Responses were categorized as follows: * Respondent: without flares and with normal inflammatory markers in the last 3 months. * Non-respondent: with flare and/or elevated inflammatory markers in the last 3 months. * Partial respondent: did not fulfill some of the criteria for complete response.
Time frame: Up to 11 years
Number of Medical Visits of Patients With Presence of Pain by Response to Anti-IL-1 Treatment
Anti-IL-1 treatments included canakinumab and anakinra. Responses were categorized as follows: * Respondent: without flares and with normal inflammatory markers in the last 3 months. * Non-respondent: with flare and/or elevated inflammatory markers in the last 3 months. * Partial respondent: did not fulfill some of the criteria for complete response.
Time frame: Up to 11 years
Number of Medical Visits of Patients With Presence of Fatigue by Response to Anti-IL-1 Treatment
Anti-IL-1 treatments included canakinumab and anakinra. Responses were categorized as follows: * Respondent: without flares and with normal inflammatory markers in the last 3 months. * Non-respondent: with flare and/or elevated inflammatory markers in the last 3 months. * Partial respondent: did not fulfill some of the criteria for complete response.
Time frame: Up to 11 years
Visual Analogue Scale (VAS) Score From Clinician Point of View
Patients' overall state of health was assessed using VAS scoring. The VAS is a straight line with a scale ranging from 0 (worst health) to 10 (best health). The clinician marks a point on the line, scoring how they perceive the patient's overall state of health. VAS was used to assess the association between anti-IL-1 treatment response and overall state of health. Anti-IL-1 treatments included canakinumab and anakinra. Treatment response was categorized as follows: * Respondent: without flares and with normal inflammatory markers in the last 3 months. * Non-respondent: with flare and/or elevated inflammatory markers in the last 3 months. * Partial respondent: did not fulfill some of the criteria for complete response.
Time frame: Up to 11 years
Visual Analogue Scale (VAS) Score From Patient Point of View
Patients' overall state of health was assessed using VAS scoring. The VAS is a straight line with a scale ranging from 0 (worst health) to 10 (best health). Patients mark a point on the line, scoring how they perceive their overall state of health. VAS was used to assess the association between anti-IL-1 treatment response and overall state of health. Anti-IL-1 treatments included canakinumab and anakinra. Treatment response was categorized as follows: * Respondent: without flares and with normal inflammatory markers in the last 3 months. * Non-respondent: with flare and/or elevated inflammatory markers in the last 3 months. * Partial respondent: did not fulfill some of the criteria for complete response.
Time frame: Up to 11 years
Ran from Mar 2023 to primary completion in May 2024, 13 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Familial Mediterranean Fever →